Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.

The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease ...

Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this ...

Two months after Roche unveiled clinical trial data that could help bring its breast cancer drug Kadcyla to early-stage patients, the company has won a speedy FDA review. And if Roche succeeds, it ...

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi. The drug is approved in combination with Pfizer ...

Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer.

(Reuters) - Health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. The Food and ...

Kadcyla® (T-DM1 or ado-trastuzumab emtansine), a new treatment for patients with HER2-positive, metastatic breast cancer to be marketed by Roche’s Genentech subsidiary, won FDA approval this ...

FDA rewards Roche with priority review for blockbuster cancer drug By John Carroll Feb 8, 2012 8:15am Biotech ...

WASHINGTON (AP) — The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating ...

FDA pertuzumab U.S. approval decision due by June 8 Drug is used with Herceptin in HER2-positive patients Roche shares up 1.9 percent Feb 7 (Reuters) - U.S. health regulators granted a priority ...